Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.
about
The MPTP Story.Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores.Biological and Clinical Implications of Comorbidities in Parkinson's Disease.Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
P2860
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Longer Duration of MAO-B Inhib ...... se: An Analysis of NET-PD LS1.
@en
Longer Duration of MAO-B Inhib ...... se: An Analysis of NET-PD LS1.
@nl
type
label
Longer Duration of MAO-B Inhib ...... se: An Analysis of NET-PD LS1.
@en
Longer Duration of MAO-B Inhib ...... se: An Analysis of NET-PD LS1.
@nl
prefLabel
Longer Duration of MAO-B Inhib ...... se: An Analysis of NET-PD LS1.
@en
Longer Duration of MAO-B Inhib ...... se: An Analysis of NET-PD LS1.
@nl
P2093
P2860
P50
P356
P1476
Longer Duration of MAO-B Inhib ...... se: An Analysis of NET-PD LS1.
@en
P2093
Anthony P Nicholas
Barbara C Tilley
Chadwick W Christine
Chizoba C Umeh
Dan Weintraub
Ivan Bodis-Wollner
James T Boyd
John C Morgan
John L Goudreau
John Y Fang
P2860
P304
P356
10.3233/JPD-160965
P577
2016-11-30T00:00:00Z